Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study
BackgroundThe long-term overall survival of children with T-cell acute lymphoblastic leukemia (T-ALL) is limited to approximately 80–85% because of a high incidence of relapse after achieving remission with intensive chemotherapy and hematopoietic stem cell transplantation (HSCT). Novel treatment st...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1096529/full |
| _version_ | 1797935873618083840 |
|---|---|
| author | Xin-Yu Li Xin-Yu Li Xia-Wei Han Xia-Wei Han Ke Huang Ke Huang Ya-Ting Zhang Hong-Gui Xu Dun-Hua Zhou Dun-Hua Zhou Lu-Hong Xu Lu-Hong Xu Jian-Pei Fang Jian-Pei Fang |
| author_facet | Xin-Yu Li Xin-Yu Li Xia-Wei Han Xia-Wei Han Ke Huang Ke Huang Ya-Ting Zhang Hong-Gui Xu Dun-Hua Zhou Dun-Hua Zhou Lu-Hong Xu Lu-Hong Xu Jian-Pei Fang Jian-Pei Fang |
| author_sort | Xin-Yu Li |
| collection | DOAJ |
| description | BackgroundThe long-term overall survival of children with T-cell acute lymphoblastic leukemia (T-ALL) is limited to approximately 80–85% because of a high incidence of relapse after achieving remission with intensive chemotherapy and hematopoietic stem cell transplantation (HSCT). Novel treatment strategies inducing long-term remission are needed to improve the outcome. Histone deacetylase inhibitors (HDACis) have been reported to be effective in a series of T-ALL cases. Preclinical studies suggested that T-ALL cells are sensitive to Chidamide, which is a selective HDACi.MethodsThis preliminary clinical study evaluated the efficacy and safety of Chidamide in combination with chemotherapy or post-HSCT for children with T-ALL at a dose of 0.5 mg/kg weight of patient twice per week for at least 6 months.ResultsIn total, 27 children with a mean age of 7.88 years were included. The high-risk proportion was 66.7%. After a median follow-up period of 37.8 months (9.5–67.9 months), the overall survival and event-free survival in the patients treated with Chidamide were 94.1 and 95.2%, respectively. All patients except two maintained persistent remission with <0.01% blast cells in minimal residual disease.ConclusionThe combination therapy with Chidamide in a case series of T-ALL shows the promising clinical efficacy and good safety in children.Clinical trial registrationhttps://www.chictr.org.cn/, identifier ChiCTR2000030357. |
| first_indexed | 2024-04-10T18:21:00Z |
| format | Article |
| id | doaj.art-2ef0cf310e9a4881b0a5792c1b6f31ff |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-10T18:21:00Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-2ef0cf310e9a4881b0a5792c1b6f31ff2023-02-02T07:09:19ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-02-011010.3389/fmed.2023.10965291096529Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective studyXin-Yu Li0Xin-Yu Li1Xia-Wei Han2Xia-Wei Han3Ke Huang4Ke Huang5Ya-Ting Zhang6Hong-Gui Xu7Dun-Hua Zhou8Dun-Hua Zhou9Lu-Hong Xu10Lu-Hong Xu11Jian-Pei Fang12Jian-Pei Fang13Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaBackgroundThe long-term overall survival of children with T-cell acute lymphoblastic leukemia (T-ALL) is limited to approximately 80–85% because of a high incidence of relapse after achieving remission with intensive chemotherapy and hematopoietic stem cell transplantation (HSCT). Novel treatment strategies inducing long-term remission are needed to improve the outcome. Histone deacetylase inhibitors (HDACis) have been reported to be effective in a series of T-ALL cases. Preclinical studies suggested that T-ALL cells are sensitive to Chidamide, which is a selective HDACi.MethodsThis preliminary clinical study evaluated the efficacy and safety of Chidamide in combination with chemotherapy or post-HSCT for children with T-ALL at a dose of 0.5 mg/kg weight of patient twice per week for at least 6 months.ResultsIn total, 27 children with a mean age of 7.88 years were included. The high-risk proportion was 66.7%. After a median follow-up period of 37.8 months (9.5–67.9 months), the overall survival and event-free survival in the patients treated with Chidamide were 94.1 and 95.2%, respectively. All patients except two maintained persistent remission with <0.01% blast cells in minimal residual disease.ConclusionThe combination therapy with Chidamide in a case series of T-ALL shows the promising clinical efficacy and good safety in children.Clinical trial registrationhttps://www.chictr.org.cn/, identifier ChiCTR2000030357.https://www.frontiersin.org/articles/10.3389/fmed.2023.1096529/fullChidamideT-cell acute lymphoblastic leukemiachildrenchemotherapyhematopoietic stem cell transplantation |
| spellingShingle | Xin-Yu Li Xin-Yu Li Xia-Wei Han Xia-Wei Han Ke Huang Ke Huang Ya-Ting Zhang Hong-Gui Xu Dun-Hua Zhou Dun-Hua Zhou Lu-Hong Xu Lu-Hong Xu Jian-Pei Fang Jian-Pei Fang Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study Frontiers in Medicine Chidamide T-cell acute lymphoblastic leukemia children chemotherapy hematopoietic stem cell transplantation |
| title | Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study |
| title_full | Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study |
| title_fullStr | Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study |
| title_full_unstemmed | Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study |
| title_short | Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study |
| title_sort | chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with t cell lymphoblastic leukemia a real world prospective study |
| topic | Chidamide T-cell acute lymphoblastic leukemia children chemotherapy hematopoietic stem cell transplantation |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1096529/full |
| work_keys_str_mv | AT xinyuli chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT xinyuli chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT xiaweihan chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT xiaweihan chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT kehuang chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT kehuang chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT yatingzhang chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT hongguixu chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT dunhuazhou chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT dunhuazhou chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT luhongxu chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT luhongxu chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT jianpeifang chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy AT jianpeifang chidamideasmaintenanceafterchemotherapyorhematopoieticstemcelltransplantationin27childrenwithtcelllymphoblasticleukemiaarealworldprospectivestudy |